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The N-end rule relates the in vivo half-life of a protein to the identity of its N-terminal residue. In the yeast
Saccharomyces cerevisiae, the UBR1-encoded ubiquitin ligase (E3) of the N-end rule pathway mediates the
targeting of substrate proteins in part through binding to their destabilizing N-terminal residues. The func-
tions of the yeast N-end rule pathway include fidelity of chromosome segregation and the regulation of peptide
import. Our previous work described the cloning of cDNA and a gene encoding the 200-kDa mouse UBR1
(E3). Here we show that mouse UBR1, in the presence of a cognate mouse ubiquitin-conjugating (E2) enzyme,
can rescue the N-end rule pathway in ubr1 S. cerevisiae. We also constructed UBR1/ mouse strains that
lacked the UBR1 protein. UBR1/ mice were viable and fertile but weighed significantly less than congenic
/mice. The decreased mass of UBR1/ mice stemmed at least in part from smaller amounts of the skeletal
muscle and adipose tissues. The skeletal muscle of UBR1/ mice apparently lacked the N-end rule pathway
and exhibited abnormal regulation of fatty acid synthase upon starvation. By contrast, and despite the absence
of the UBR1 protein, UBR1/ fibroblasts contained the N-end rule pathway. Thus, UBR1/ mice are mosaics
in regard to the activity of this pathway, owing to differential expression of proteins that can substitute for the
ubiquitin ligase UBR1 (E3). We consider these UBR1-like proteins and discuss the functions of the mam-
malian N-end rule pathway.
Many biological processes are regulated by circuits that in-
volve conditionally or constitutively short-lived proteins. Fea-
tures of proteins that confer metabolic instability are called
degradation signals, or degrons (16, 36, 72). The essential
component of one degradation signal, termed the N-degron, is
a destabilizing N-terminal residue of a protein (3, 71). A set of
amino acid residues that are destabilizing in a given cell yields
a rule, called the N-end rule, which relates the in vivo half-life
of a protein to the identity of its N-terminal residue. Variants
of the underlying proteolytic system, called the N-end rule
pathway, are present in all organisms examined, from mam-
mals and plants to fungi and prokaryotes (51, 71).
In eukaryotes, an N-degron consists of two determinants: a
destabilizing N-terminal residue and an internal lysine of a
substrate protein (4, 29, 66). The recognition of N-degron by
the targeting machinery involves stochastic selection of second-
determinant Lys residues from among the substrate’s sterically
suitable lysines (4, 29, 66). This Lys residue is the site of
formation of a substrate-linked multiubiquitin (multi-Ub)
chain (10, 48, 78). The N-end rule pathway is, thus, one path-
way of the Ub system (15, 20, 24–26, 57). Ub is a 76-residue
protein whose covalent conjugation to other proteins plays a
role in a vast range of biological processes, including cell
growth, division, differentiation, and responses to stress (24,
26, 49, 74). In most of these processes, Ub acts through routes
that involve processive degradation of Ub-protein conjugates
by the 26S proteasome, an ATP-dependent protease (14, 52,
75).
The N-end rule has a hierarchic structure. In the yeast Sac-
charomyces cerevisiae, Asn and Gln are tertiary destabilizing
N-terminal residues in that they function through their deami-
dation, by the NTA1-encoded N-terminal amidase (Nt-ami-
dase), to yield the secondary destabilizing N-terminal residues
Asp and Glu (6, 63). The destabilizing activity of N-terminal
Asp and Glu requires their conjugation, by the ATE1-encoded
Arg-tRNA-protein transferase (R-transferase), to Arg, one of
the primary destabilizing residues (7, 40, 71) (Fig. 1). These
latter residues are bound directly by UBR1 (N-recognin), the
E3 (recognition) component of the N-end rule pathway. S.
cerevisiae UBR1 is a 225-kDa E3 which binds to potential
N-end rule substrates through its type 1 and type 2 substrate-
binding sites. The type 1 site binds the basic N-terminal resi-
dues Arg, Lys, and His. The type 2 site binds the bulky hydro-
phobic N-terminal residues Phe, Leu, Trp, Tyr, and Ile (34, 71)
(Fig. 1). S. cerevisiae UBR1 also contains a third substrate-
binding site which targets proteins such as CUP9 and GPA1
through their internal (non-N-terminal) degrons (9, 56, 68).
The UBR1-encoded E3, in a complex with the RAD6-encoded
E2 (Ub-conjugating) enzyme, catalyzes the synthesis of a sub-
strate-linked multi-Ub chain (17, 71) and may also mediate the
delivery of substrates to the 26S proteasome (80). UBR1 con-
tains a functionally essential RING-H2 domain (79), a feature
of many otherwise distinct E3s (28, 70, 78).
The term Ub ligase denotes either an E2-E3 complex or its
E3 component. The numerous proteolytic pathways of the Ub
system have in common their dependence on Ub conjugation
and the proteasome and differ largely through their utilization
of distinct E2-E3 complexes. The RAD6-UBR1 (E2-E3) Ub
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ligase of the N-end rule pathway is one example of such a
complex. Specific E3s recognize (bind to) specific degrons of
their protein substrates. The diversity of E3s underlies the
enormous range of substrates that are recognized and de-
stroyed by the Ub system in ways that are regulated both
temporally and spatially. There are dozens of E3s in S. cerevi-
siae and possibly hundreds of distinct E3s in mammals (78).
In contrast to yeast, where N-terminal Asn and Gln are
deamidated by a single Nt-amidase, in mammals there are two
enzymes, NtN-amidase and NtQ-amidase, which are specific for
N-terminal Asn and Gln, respectively (19, 32, 64) (Fig. 1). In
vertebrates, the set of secondary destabilizing residues contains
not only Asp and Glu but also Cys, the latter being a stabilizing
residue in the yeast N-end rule (11, 18). The two known species
of mammalian R-transferase, ATE1-1 and ATE1-2, are pro-
duced through alternative splicing of ATE1 pre-mRNA (33).
The substrate specificities of ATE1-1 and ATE1-2 are similar
to those of the ATE1-encoded R-transferase of S. cerevisiae in
that they can arginylate N-terminal Asp and Glu but cannot
arginylate N-terminal Cys (33). However, recent work revealed
that mouse ATE1/ cells are incapable of arginylating any of
the three secondary destabilizing N-terminal residues—Asp,
Glu, and Cys (Y. T. Kwon, A. Kashina, I. Davydov, and A.
Varshavsky, unpublished data).
The known functions of the N-end rule pathway include the
control of peptide import in S. cerevisiae through the condi-
tional degradation of CUP9, a transcriptional repressor of the
peptide transporter PTR2 (1, 9, 68). It remains to be deter-
mined whether the N-end rule pathway has similar import-
regulating functions in prokaryotes and multicellular eu-
karyotes. The S. cerevisiae N-end rule pathway is also essential
for chromosome stability, through degradation, at the met-
aphase-anaphase transition, of a fragment of cohesin com-
plexes that hold together sister chromatids (51). Given the
evolutionary conservation of separase and cohesin (76), this
function of the yeast N-end rule pathway may be relevant to
other eukaryotes as well.
Besides CUP9 and SCC1, several other proteins were also
found to be substrates of the N-end rule pathway. These pro-
teins include Sindbis virus RNA polymerase (and homologous
polymerases of other alphaviruses) (13), HIV integrase (45), a
bacterial protein, p60, which is secreted by Listeria monocyto-
genes into the cytosol of infected mammalian cells (59), the
mammalian GTPase-accelerating (GAP) proteins RGS4 and
RGS16 (12), the S. cerevisiae GPA1-encoded G protein (43,
56), and the encephalomyocarditis (EMC) virus 3C protease
(37). Physiological functions, if any, of the degradation of these
proteins by the N-end rule pathway are either unknown or
have not been established definitively.
In yeast only one E3, encoded by UBR1, mediates the rec-
ognition of substrates by the N-end rule pathway (8, 71). Stud-
ies of the Ub-dependent proteolysis in rabbit reticulocyte ex-
FIG. 1. (A) The N-end rule pathway in mammals (12, 32, 33). N-terminal residues are indicated by single-letter abbreviations for amino acids.
The ovals denote the rest of a protein substrate. The Asn-specific N-terminal amidase (NtN-amidase) NTAN1 converts N-terminal Asn into Asp
(19, 32). N-terminal Gln is deamidated by a distinct NtQ-amidase, NTAQ1, which remains to be characterized. In mammals, the secondary
destabilizing N-terminal residues Asp, Glu, and Cys are arginylated by the Arg-tRNA-protein transferases (R-transferases) encoded by ATE1 (33
and Y. T. Kwon, A. Kashina, and A. Varshavsky, unpublished data). The set of primary destabilizing N-terminal residues—Arg, Lys, His, Phe, Leu,
Trp, Tyr, and Ile—is recognized in mammals by at least three distinct E3 enzymes of similar binding specificities, including the UBR1-encoded E3
and UBR2 (see Discussion). N-terminal Ala, Ser, and Thr are primary destabilizing residues in mammals but are stabilizing residues in S. cerevisiae
(18, 22). An E3 that recognizes these N-terminal residues remains to be characterized. In mammals, either of the two highly similar Ub-conjugating
(E2) enzymes, HR6A and HR6B (E214K), can be a component of E2-E3 complexes (Ub ligases) that mediate ubiquitylation of N-end rule
substrates. The term “Ub ligase” is used to denote either an E2-E3 complex or its specific E3 component. A targeted, multi-Ub chain-bearing
substrate is degraded by the 26S proteasome. (B) The N-end rule pathway in the yeast S. cerevisiae differs from its mammalian counterpart by the
presence of a single Nt-amidase, NTA1, which mediates deamidation of N-terminal Asn or Gln (6) by Cys being a stabilizing residue; by the
absence of E3 that recognizes N-terminal Ala, Ser, and Thr; and by the presence of a single E3, UBR1, that recognizes other primary destabilizing
N-terminal residues (71).
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tracts suggested that the same may be true in mammalian cells,
since only one E3 of the N-end rule pathway, called E3, was
apparent in these extracts (23). However, the cloning of cDNA
and genes encoding mouse UBR1 (E3) indicated the exis-
tence of at least two UBR1 homologs in the mouse (and hu-
man) genome, termed UBR2 and UBR3 (35). The sequences of
UBR2 and UBR3 cDNAs and genes (Y. T. Kwon, T. Tasaki,
and A. Varshavsky, unpublished data) suggested that at least
mouse UBR2 may functionally overlap with UBR1. To address
this and related questions, we initiated genetic and biochemi-
cal dissection of the UBR protein family in the mouse. In the
present study, the first in a projected series, we constructed and
analyzed mouse strains lacking UBR1.
MATERIALS AND METHODS
Strains and plasmids. The S. cerevisiae strains used were JD52 (MATa ura3-52
his3-200 leu2-3,112 trp1-63 lys2-801) (30) and the ubr1 strain AVY107
(MATa ura3-52 his3-200 leu2-3,112 trp1-63 lys2-801 ubr1::myc3) (H. Rao and
A. Varshavsky, unpublished data). Cells were grown in rich medium (yeast-
peptone-dextrose) or in synthetic glucose-containing medium (standard-dextrose
[SD]) (58). The pUB23-X plasmids (X  Arg, Leu, or Met) (3) were used for
expressing Ub–X–-galactosidase (gal) proteins from the galactose-inducible
PGAL promoter. Transformation of S. cerevisiae was performed using the lithium
acetate method (2).
Construction of mouse strains lacking UBR1. BAC3, a BAC clone containing
the mouse UBR1 gene (35), was the source of homology arms. The 7.0-kb
ClaI-NsiI fragment of BAC3 (encompassing exons 3 and 4) and the 1,670-bp
PvuII-NsiI fragment (encompassing exons 6 to 8) were used as the long and short
homology arms of the targeting vector, respectively. These fragments were in-
serted into pPGK-SA containing a PGK/neo cassette and a PGK/TK cassette
(32), yielding pUBR1-KO (Fig. 2A). The ClaI-linearized targeting vector (Fig.
2A) was electroporated into CJ7 embryonic stem (ES) cells (derived from the
mouse strain 129/SvJ) (2). Selection with G418 (at 0.4 mg/ml) and 1-(2-deoxy,
2fluoro--D-arabinofuranosyl)-5-iodouracil (FIAU; at 0.4 M) was started 24 h
after electroporation. Correctly targeted ES cells were identified by PCR and
Southern hybridization by using the 5 and 3 probes (Fig. 2A to C). Cells of the
10 independent ES cell clones were injected into 3.5-days postcoitum C57BL/6J
blastocysts. The resulting male chimeras were bred with C57BL/6J females to test
for germline transmission of the mutated UBR1 gene. The UBR1/ mice re-
sulting from this cross (5 of 10 independent ES clones were found to populate the
germline in these tests) were intercrossed to produce UBR1/ mice in the mixed
129/C57 strain background. Alternatively, the initial male chimeras were mated
with 129/SvEv females, yielding, through the analogous procedures, UBR1/
mice in the strain 129 background. For genotyping the tail-derived DNA was
analyzed by PCR or digested with either SphI or BamHI and analyzed by
Southern hybridization. The 0.8- and 1.1-kb PCR-produced fragments (indicated
in Fig. 2A) were used as the 5 and 3 Southern hybridization probes, respec-
tively.
Cloning of the mouse HR6A cDNA. We searched GenBank’s expressed se-
quence tag (EST) database for a close mouse homolog of the mouse E214K
Ub-conjugating enzyme (m HR6B, accession no. U57690). A putative amino acid
sequence deduced from EST clones was 95% identical to that of mouse HR6B
(E214K). The corresponding full-length cDNA was amplified by reverse tran-
scription (RT)-PCR using total RNA isolated from skeletal muscle (33). First-
strand cDNA was synthesized using Superscript II polymerase (GIBCO, Fred-
erick, Md.), and PCR was carried out using primers specific for the 5 end
(GGCGGATCCTGAGCCCGCTAAAGCCATGTCGAC, forward primer; sin-
gle and double underlinings denote the BamHI restriction site and start codon,
respectively) and the 3 end (CTGGCGCGACTGTTGACTCAGGGTCTCGA
GCGG, reverse primer; single and double underlinings denote the XhoI restric-
tion site and stop codon, respectively) of the mouse HR6A open reading frame
(ORF). For the expression of mouse HR6A in S. cerevisiae, the amplified
mHR6A cDNA was cloned into BamHI-XhoI-cut p413-MET25 and p415-
MET25 (46), yielding p413-MET25-mHR6A and p415-MET25-mHR6A, respec-
tively. For the expression of mouse HR6B (E214K) in S. cerevisiae, its ORF was
amplified by PCR from the plasmid 44.83 encoding mHR6B (E214K) (a gift from
H. P. Roest, Erasmus University, Rotterdam, The Netherlands) and was then
subcloned into BamHI-XhoI-cut p413-MET25 and p415-MET25 (46), yielding
p413-MET25-E214K and p415-MET25-E214K, respectively.
FIG. 2. Construction of UBR1/ mice. (A) Top diagram, a restric-
tion map of the 	24-kb 5-proximal region of the 	120-kb mouse
UBR1 gene. Middle diagram, the targeting vector. Bottom diagram,
the deletion and/or disruption UBR1 allele. Exons are denoted by
solid vertical rectangles. The directions of transcription of the neomy-
cin (neo) and the thymidine kinase (tk) genes are indicated. Homolo-
gous recombination resulted in the replacement of the UBR1 exons 4
to 6 with the neo cassette. Exon 4, marked by an asterisk, contains
Gly147 and Asp150, the residues that are essential, in S. cerevisiae
UBR1, for binding type 1 destabilizing N-terminal residues (see Re-
sults). Exon 6, also marked by an asterisk, contains Asp233 and His236,
the residues that are essential, in S. cerevisiae UBR1, for binding type
2 destabilizing N-terminal residues (see Results). Probes used for
Southern hybridization are indicated by solid rectangles. Restriction
sites: Sp, SphI; Cl, ClaI; BI, BamHI, Ns, NsiI, PII, PvuII. (B) PCR
analysis of mouse tail DNA. The primers were 5-GCCACTTGTGT
AGCGCCAAGTGCCAG-3 (for neo; forward), 5-GAGATAGGAA
ACTGCATGCGCTGC-3 (for UBR1; forward), and 5-CAAGAGT
GCAACAGTTACCACATG-3 (for UBR1; reverse). DNA bands
corresponding to the wild-type (wt) and mutant (mut) UBR1 alleles are
indicated on the right. (C) Southern analysis of BamHI-cut (3 probe)
and SphI-cut (5 probe) tail DNA from /, UBR1/, and UBR1/
mice. The 3 probe detected 13- and 5.5-kb UBR1 fragments in
BamHI-cut DNA corresponding to the wild-type and mutant UBR1
alleles, respectively. The 5 probe detected 16- and 10-kb fragments in
the same SphI-cut alleles. The depicted organization of the deletion
and/or disruption UBR1/ allele was additionally verified using
Southern analysis with other restriction endonucleases (data not
shown). (D) Northern analysis. Total electrophoretically fractionated
RNA from brain, testis, or liver of/ and UBR1/ mice was probed
either with the UBR1 cDNA fragment (nucleotides 555 to 888) which
was deleted in the UBR1/ allele (gel a) or with the 	2-kb cDNA
fragment (nucleotides 116 to 2124) that contained both the deleted
region (nucleotides 532 to 885) and its flanking sequences (gel b) or
with the human -actin cDNA fragment (gel c). (E) Immunoblot
analysis of total extracts from liver, skeletal muscle, and EFs with
affinity-purified antibody (38) against the N-terminal 	35-kDa frag-
ment of mouse UBR1 (gels a to c) or with affinity-purified antibody
specific for the 2-1 UBR1 peptide (see Materials and Methods) en-
coded by the deleted region of UBR1 in the UBR1 allele (gel d).
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Subcloning and expression of mouse UBR1 cDNA in S. cerevisiae. Because the
mouse UBR1 cDNA was toxic to all of the tested Escherichia coli strains (data not
shown), we subcloned it directly in S. cerevisiae. An AnfII (blunt-ended)/ClaI-
produced cDNA fragment containing the 5.3-kb mouse UBR1 ORF in the MR26
plasmid (35) was ligated to SmaI/ClaI-cut p414-MET25. The ligation mixture
was used to transform the ubr1 S. cerevisiae strain AVY107 on SD plates lacking
Trp, followed by incubation at 30°C for 3 to 4 days. Selected transformants were
grown in SD (lacking Trp) liquid medium, followed by isolation of the plasmid
DNA and by PCR screening for the presence of full-length UBR1 ORF. The
resulting plasmid, pMET414-mUBR1, expressed the 200-kDa mouse UBR1 in S.
cerevisiae.
Assay of gal activity and pulse-chase analysis in S. cerevisiae. For the assay
of gal activity, S. cerevisiae cells in a 5-ml culture (A600 of 	1) were pelleted by
centrifugation and resuspended in 5 ml of buffer Z (10 mM KCl, 1 mM MgSO4,
50 mM -mercaptoethanol, 60 mM Na2HPO4, 40 mM NaH2PO4 [pH 7.0]). After
determining the A600 of the suspension, 50- or 100-l samples were diluted to 1
ml with buffer Z, and 0.1% SDS (20 l) and CHCl3 (50 l) were then added; the
suspension was vortexed for 10 to 15 s and incubated for 15 min at 30°C, followed
by the addition of 0.2 ml of o-nitrophenyl--D-galactopyranoside (ONPG) (4
mg/ml in buffer Z) and incubation at 30°C, until a medium-yellow color had
developed, at which point the reaction was stopped by the addition of 1 M
Na2CO3 (0.4 ml). The mixture was centrifuged for 5 min at 1,100 
 g, and A420
and A500 of the samples were measured. The ONPG units (UONPG) of gal
activity were calculated as follows: UONPG  1,000 




 (A600), where (t) and (v) were the time of incubation (min) and the
sample volume (ml), respectively.
For pulse-chase analysis, cells were grown at 30°C in SD (lacking Ura, Trp, and
Leu) medium, harvested by centrifugation, washed twice with sterile water, and
inoculated into SG (lacking Ura, Trp, Leu, and Met) medium to a final A600 of
0.2. When the A600 reached 1.0, cells from a 10-ml culture were harvested by
centrifugation, washed with 0.8 ml SG (lacking Ura, Trp, Leu, and Met) medium,
resuspended in 0.4 ml of the same medium, and labeled for 5 min at 30°C with
35S-methionine–cysteine (0.16 mCi of 35S-EXPRESS; New England Nuclear,
Boston, Mass.). Cells were pelleted and resuspended in 0.4 ml of SG (lacking
Ura, Trp, Leu, and Met) medium containing 10 mM L-methionine and 5 mM
L-cysteine. Samples (0.1 ml) were taken at the indicated time points, followed by
preparation of extracts and immunoprecipitation (34) by using a monoclonal
anti-gal antibody (Promega, Madison, Wis.).
Overexpression, labeling, and purification of Ub-X-eK-DHFR-His6 proteins.
A pT7-UbXeKDHFRhis plasmid (X  Met, Arg, or Phe) (11) was transformed
into E. coli BL21(DE3) (2). Following the addition of isopropyl-1-thio--D-
galactopyranoside (IPTG), the cells were labeled with 35S-methionine–cysteine
(35S-EXPRESS; New England Nuclear) as described previously (32). The cells
were collected by centrifugation and disrupted by sonication, and 35S-labeled
Ub-eK-DHFR-His6 (Ub-X-DHFR) test proteins were purified by affinity chro-
matography under nondenaturing conditions by using the Ni-NTA Spin Kit
(Qiagen, Chatsworth, Calif.). The eluted proteins were dialyzed against a solu-
tion containing 1 mM MgCl2, 1 mM dithiothreitol (DTT), 0.1 M Tris-HCl (pH
7.7) and were rapidly frozen and stored at 80°C in samples that were to be
thawed just once. The specific radioactivity of [35S]Ub-X-DHFR proteins was
5 
 105 to 10 
 105 cpm/g.
Extracts of skeletal muscle and embryonic fibroblast (EF) cells. To prepare
muscle extracts, leg muscles from three to six / male mice or their littermate
(also male) UBR1/ counterparts (strain 129 background) were combined and
homogenized in 20 mM Tris (pH 7.6) containing 1 mM -mercaptoethanol, 1%
glycerol, 1 mM EDTA, 1 mM EGTA, 50 M chymostatin, and 50 M E64
(Sigma, St. Louis, Mo.) using a rotor-stator homogenizer (Biospec Products,
Bartlesville, Okla.).
Homogenates were centrifuged at 30,000 
 g for 30 min to remove myofibrils,
followed by centrifugation of the supernatants at 100,000 
 g for 1 h. The
resulting extracts were either assayed directly or fractionated on DEAE-cellulose
(23, 61) to produce fraction II (which contained the proteasome and most of the
Ub-system enzymes) and the flowthrough fraction I (which contained Ub and
	70% of proteins in the initial extract). Both whole-cell extracts and fraction II
were dialyzed against a solution containing 20% glycerol, 1 mM DTT, 5 mM
MgCl2, 50 mM Tris (pH 7.6) and were stored at 80°C in samples that were to
be thawed and used only once. The same procedures were employed to prepare
extracts from / and UBR1/ EF cells, except that a Dounce homogenizer
was used to disrupt the cells.
In vitro proteolysis and Ub conjugation assays. Degradation assays were
carried out in samples of 0.1 ml containing the following components: 20 mM
Tris-HCl (pH 7.6), 5 mM MgCl2, 2 mM DTT, ATP-regenerating system (10 g
of creatine phosphokinase and 10 mM creatine phosphate), 1 mM ATP, 25 g of
purified Ub, 50 M bestatin, a dipeptide at 2 mM (when present), 	0.5 mg of
dialyzed whole-cell extract, and a 35S-labeled X-DHFR (X-eK-DHFR-His6) test
substrate, produced from Ub-X-eK-DHFR-His6 through the cleavage by deubiq-
uitylating enzymes (DUBs) in the extract. The following dipeptides were used:
Lys-Ala, Ala-Lys, Phe-Ala, and Ala-Phe (Sigma, St. Louis, Mo.). Dipeptides
were stored at 20°C at 0.5 M in 10 mM K-HEPES, pH 7.5. Bestatin (Sigma)
was added to decrease degradation of dipeptides in the extract (12, 53). Control
experiments (not shown) showed that the addition of bestatin alone did not
significantly inhibit the degradation of test proteins by the N-end rule pathway.
In some experiments the reaction mixtures were incubated for 10 min without
ATP, followed by the addition of ATP and an ATP-regenerating system. Incu-
bations were carried out at 37°C. Samples of 10 l were withdrawn in the course
of incubation, and the degradation of [35S]Ub-X-DHFR proteins was assessed by






a 1  100%
where X was the amount of TCA-soluble 35S (cpm); Y was the total amount of
35S (cpm) in the same sample; and a was the number of Met residues in a
Ub-X-DHFR test protein (a  10 for Ub-Met-DHFR; a  9 for the other
Ub-X-DHFRs). The a-1 term corrected for the presence of one Met residue in
Ub. To determine TCA-soluble 35S, a 10-l sample was added to a tube con-
taining 90 l of ice-cold 5.6% TCA. The tube was briefly vortexed, incubated on
ice for 10 min, and centrifuged in a microcentrifuge for 10 min at 4°C. 35S in a
fraction of supernatant was then determined using scintillation counter.
To assay Ub conjugation to a test protein, fraction II (35 g of protein, 20 l
total volume) was incubated with 125I-labeled -lactalbumin (	150,000 cpm, 	1
M) and unlabeled Ub (50 M) in buffer A (20 mM Tris-HCl [pH 7.6], 20 mM
KCl, 5 mM MgCl2, 2 mM AMP-PNP, 1 mM DTT, 30 M MG132 [Sigma], and
10% glycerol). Samples (20 l) were incubated at 37°C for 1 h. The reactions
were terminated by the addition of 5
 Laemmli sample buffer (6 l) (2) followed
by SDS–13% polyacrylamide gel electrophoresis (PAGE) and quantitation by
using PhosphorImager (Molecular Dynamics, Sunnyvale, Calif.). To assay Ub
conjugation to endogenous muscle proteins, fraction II (35 g of protein) was
incubated with 125I-Ub (	150,000 cpm, 5 to 10 M) in buffer A for 1 h at 37°C,
followed by SDS-PAGE analysis as described above. Purified E214K(C88S), a
dominant-negative inhibitor of UBR1 (E3) (65), or Lys-Ala, a type 1 dipeptide
inhibitor of UBR1 (18), was added to some of the assays. Human -lactalbumin
was radioiodinated by using the chloramine T method (61).
Antibodies to mouse UBR1 and immunoblotting. Rabbit polyclonal antibodies
to mouse UBR1 were raised against the synthetic peptides EMDPDLEKQ
EESVQ (UBR1 residues 54 to 67; antibody UBR1 [1-1]), HEPGRAGTT
KESLH (UBR1 residues 66 to 179; antibody UBR1 [2-1]), and EYLDRNNK
FNFQGYSQDK (UBR1 residues 451 to 468; antibody UBR1 [3-1]). The anti-
bodies were affinity-purified using immobilized peptides. The sequence of the
second peptide (antibody UBR1 [2-1]) was in the region of UBR1 that was
absent from the UBR1 allele.
For immunoblotting, mouse tissues were homogenized in 50 mM Tris-HCl
(pH 7.2) containing 0.5% SDS, 5 mM EDTA, 0.25 mM phenylmethylsulfonyl
fluoride (PMSF; freshly prepared as a 125 mM solution in isopropanol), and
protease inhibitor tablets containing inhibitors of several proteases (Boehringer
Mannheim, Indianapolis, Ind.). The samples were centrifuged at 12,000 
 g for
1 h, and proteins in the supernatants (50 to 70 g per lane) were subjected to
SDS–7.5% PAGE, followed by electrophoretic transfer to Immobilon-P mem-
branes (Millipore, Bedford, Mass.). The membranes were blocked with TBS-T
buffer (20 mM Tris-HCl [pH 7.6], 137 mM NaCl, 0.1% Tween 20) containing 5%
nonfat dry milk (Carnation) and thereafter incubated with one of the above
antibodies to mouse UBR1 (diluted 1:1,000), washed with TBS-T buffer, incu-
bated with horseradish peroxidase (HRP)-coupled goat anti-rabbit immunoglob-
ulin G (Bio-Rad, Hercules, Calif.), and developed using a ECL kit (Amersham,
Piscataway, N.J.) (21). Another antibody to mouse UBR1 employed in the
present work was previously raised against the 35-kDa N-terminal fragment of
UBR1 (38). This affinity-purified polyclonal rabbit antibody was used at a 1:1,500
dilution.
Immortalization of embryonic fibroblasts, transfection, and pulse-chase anal-
ysis. Primary EFs were isolated from 13.5-day old (E13.5) / and littermate
UBR1/ embryos of the mixed (129/C57) genetic background as described
previously (32, 54). EFs were grown in Dulbecco’s modified Eagle medium-F12
medium (GIBCO) supplemented with 15% fetal bovine serum, antibiotics, and
2 mM L-glutamine. Permanent cell lines were established from primary EFs
through crisis-mediated immortalization over 2 months by replating, every 3
days, 	1.5 
 106 cells onto a 10-cm-diameter plate. DNA transfection efficiency
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was considerably higher with immortalized EFs than with primary EFs (data not
shown).
Immortalized / and UBR1/ EF cell lines were transiently transfected,
using Lipofectamine (GIBCO), with pRC/dhaUbXnsP4gal (X  Met, Arg, or
Phe) expressing the fusion proteins DHFRh-UbR48-X-nsP4gal (superscript “h”
denotes the ha epitope [2]) from the PCMV promoter. These and analogous
Ub/protein/reference (UPR)-based fusions (39, 66) are cotranslationally cleaved
in vivo at the Ub-protein junction, yielding, in the present case, the reference
protein DHFRh-UbR48 (DHFR-Ub) and a test protein X-nsP4gal (see Re-
sults). Similarly, the transfected plasmids pcDNA3-flag-DHFR-ha-Ub-X-
nsP4-flag (X  Met, Arg, or Tyr) expressed fDHFRh-UbR48 (DHFR-Ub) and
X-nsP4f (X-nsP4) (full-length nsP4 of the Sindbis virus bearing N-terminal Met,
Arg, or Tyr) (superscript f denotes the flag epitope) (2). The latter plasmids were
produced by subcloning PCR-produced SmaI-XbaI fragments encoding X-nsP4-
flag into EheI-XbaI-cut UPR vector pcDNA3(dEheI)FDHUMCM (J. Sheng and
A. Varshavsky, unpublished data) encoding fDHFRh-UbR48. About 24 h after
transfection cells were labeled with 35S-methionine–cysteine (35S-EXPRESS;
New England Nuclear), followed by chases for 0, 1, and 2 h in the presence of
cycloheximide, preparation of extracts, immunoprecipitation, SDS–10% PAGE,
autoradiography, and quantitation using a PhosphorImager, essentially as de-
scribed previously (32, 39, 66). Cells expressing X–-gal(X-nsP4gal) tests were
labeled for 1 h without a chase and then processed as above.
Blood plasma measurements. UBR1/ mice (in the inbred strain 129 back-
ground) and their congenic / littermates (produced through matings of
UBR1/ mice) were used. The experiments were performed twice (experiments
1 and 2), with 28 pairs of animals total. Blood from 12 pairs of mice, with water
and chow diet ad libitum, was collected before fasting. Blood from 8 pairs of mice
was collected after 24 h of food deprivation (from 10 a.m. to 10 a.m., with free
access to water). Blood from 8 pairs of mice was collected after 24 h of fasting
followed by 24 h of refeeding, with chow diet ad libitum. Body weights were
determined before and after fasting and refeeding. Blood was withdrawn by
cardiac puncture (	0.6 ml per animal) and transferred into heparin-coated
tubes. The plasma fraction was prepared by centrifugation immediately thereaf-
ter, quickly frozen, and stored at 70°C before the measurements. The levels of
glucose, triglycerides, and cholesterol, together with sodium, potassium, chloride,
calcium, phosphorus, blood urea nitrogen, creatine, total protein, albumin, total
bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT),
alkaline phosphatase, and -glutamyltransferase (GGT) were determined by the
Biomedical Testing Services (San Diego, Calif.) by using a Vitros 950 chemistry
analyzer (Johnson and Johnson, Rochester, N.Y.). Two independent experi-
ments, 1 and 2, yielded average values that differed by, at most, 1% of the
measured values for sodium, potassium, and chloride, 6.4% for calcium and
phosphorus, 3.2% for glucose, 5.3% for triglycerides and cholesterol, and 13%
for albumin, urea nitrogen, total protein, GGT, AST, and ALT. The level of
glucose was independently determined by the hexokinase/G6PD method, using a
commercial kit (Sigma).
Double-mutant NTAN1/ UBR1/ mouse strains. NTAN1/ mice (32) of
the 129Sv background (129SvJ/129SvEv) and UBR1/ mice of the mixed
(129SvJ and C57BL/6) background were mated to produce F1 progeny heterozy-
gous for both genes. Siblings were then intercrossed to produce, in particular, the
NTAN1/ UBR1/ progeny, as determined by using PCR and tail-derived
DNA, with primers specific for NTAN1 (32) and UBR1 (Fig. 2A and B).
Other methods. For Northern hybridization, total RNA was isolated from the
brain, testis, skeletal muscle, and EF cells of / and UBR1/ mice as de-
scribed previously (32). RNA was fractionated by electrophoresis in formalde-
hyde–1% agarose gels, blotted onto Hybond N membranes (Amersham), and
hybridized with 32P-labeled cDNA probes (2). The fasting and refeeding proto-
cols for Northern analysis were identical to those used for plasma chemistry
measurements, except that fasting and refeeding were carried out for 48 and
24 h, respectively. For histological examination tissues and organs were fixed in
Bouin’s fixative or 10% buffered formalin, paraffin embedded, sectioned, and
either stained with hematoxylin and eosin or assayed for apoptosis by using the
terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling
(TUNEL) technique and an in situ cell death detection kit (Boehringer Mann-
heim), with fluorescein-dUTP. For behavioral tests, the strain 129 UBR1/ mice
and their congenic / littermates (produced through matings of UBR1/
mice) were used. The rotarod, weight retention, and coat-hanger tests were
performed as described previously (32).
Nucleotide sequence accession number. The nucleotide sequence of mouse
HR6A cDNA was submitted to GenBank with accession no. AF383148.
RESULTS
Mouse UBR1, in the presence of cognate mouse E2, rescues
the N-end rule pathway in ubr1 S. cerevisiae. The amino acid
sequence encoded by the mouse UBR1 ORF contained all 14
sequences of peptide-size UBR1 fragments isolated from two
independently produced preparations of rabbit E3 (35), in-
dicating that mouse UBR1 was, in fact, E3, the N-recognin of
the N-end rule pathway. To verify directly whether mouse
UBR1 could function as N-recognin in vivo, we asked whether
its expression in ubr1 S. cerevisiae, which lacked the N-end
rule pathway, could rescue the pathway in these cells. Since the
full-length mouse UBR1 cDNA was found to be toxic to E. coli,
we constructed a mouse UBR1-expessing plasmid directly in S.
cerevisiae (see Materials and Methods). ubr1 S. cerevisiae,
which lacked S. cerevisiae UBR1 but retained RAD6, the
UBR1-interacting E2 enzyme of the N-end rule pathway (71),
were cotransformed with a pair of plasmids that expressed
mouse UBR1 from the PMET25 promoter and one of three test
proteins, expressed as Ub-X-gal fusions (X  Arg, Leu, or
Met). In eukaryotes, Ub fusions are cleaved cotranslationally
by DUBs after the last residue of the Ub moiety (69, 73). With
Ub-X-gals, this cleavage yielded X-gal proteins bearing ei-
ther Arg, Leu, or Met at their N termini. Arg and Leu are,
respectively, type 1 and type 2 primary destabilizing residues in
the N-end rule. Met is a stabilizing residue (71).
Previous work showed that the steady-state level of an
X-gal protein is a sensitive measure of its metabolic stability
(17, 33, 42). The relative levels of X-gals in S. cerevisiae were
determined by measuring the enzymatic activity of gal in
yeast extracts. We found that the activity of Arg-gal and
Leu–-gal in extracts from ubr1 cells expressing mouse
UBR1 was reproducibly 	20% lower than that in control
ubr1 extracts, whereas the activity of Met-gal was not af-
fected by the presence of mouse UBR1 (Fig. 3A and data not
shown). In addition, a	90-kDa, long-lived gal cleavage prod-
uct that is specific for short-lived X-gal test proteins (3) was
observed in pulse-chase assays with S. cerevisiae that coex-
pressed Arg-gal and mouse UBR1 but not with Arg-gal in
the absence of mouse UBR1 (data not shown). The detectable
but low N-recognin activity of mouse UBR1 in S. cerevisiae may
be caused by a poor fit between the yeast RAD6-encoded E2
enzyme and the mouse counterpart of yeast UBR1. Therefore
we asked whether coexpression of mouse HR6B (E214K), a
homolog of S. cerevisiae RAD6, could increase the activity of
mouse UBR1 in yeast without decreasing its specificity. In-
deed, coexpression of mHR6B and mouse UBR1 increased the
activity of the N-end rule pathway in ubr1 S. cerevisiae (Fig.
3A). Koken et al. (31) described a human E2 enzyme, termed
HR6A, whose deduced sequence was 95% identical to that of
human HR6B (E214K). We used RT-PCR to isolate a cDNA
encoding the mouse counterpart (mHR6A) of human HR6A.
The deduced sequence of mHR6A was 95% identical to that of
the mouse HR6B (E214K) enzyme and 99% identical to the
sequence of human HR6A (data not shown). The mouse
HR6A E2 enzyme was found to be indistinguishable from
mHR6B (E214K) in its ability to cooperate with mouse UBR1
in mediating the activity of the N-end rule pathway in ubr1 S.
cerevisiae (Fig. 3A). No additional enhancement of the N-end
rule pathway’s activity was observed upon coexpression of
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mouse UBR1, mHR6A, and mHR6B (Fig. 3A). Thus, both
mHR6A and mHR6B (E214K) are likely to be the cognate E2
components of the UBR1-containing Ub ligase.
The above results, based on the measurements of X-gal
concentrations (Fig. 3A), were in agreement with direct (pulse-
chase) assays under the same conditions: significant degrada-
tion of Arg-gal in ubr1 S. cerevisiae was observed only upon
coexpression of mouse UBR1 and a cognate mouse E2 enzyme
(Fig. 3C and D). The N-end rule pathway’s activity conferred
on ubr1 S. cerevisiae through a combination of mouse UBR1
and a cognate E2 enzyme (mHR6A or mHR6B) was signifi-
cant but much lower than the activity of this pathway in wild-
type (UBR1) S. cerevisiae (Fig. 3A). This is not surprising, given
the evolutionary distance between fungi and mammals and the
likely presence of substrate targeting steps in the yeast N-end
rule pathway that can be compromised through interactions
with a mammalian version of Ub ligase.
In contrast to yeast, where primary destabilizing residues are
either of type 1 or of type 2 (see the introduction), there are
also type 3 N-end rule substrates in mammals. The substrates
of this latter class bear N-terminal Ala, Ser, or Thr (18) and are
recognized by a distinct E3, termed E3 (22). The molecular
identity of E3 is unknown. We asked whether mouse UBR1,
in the presence of either mHR6A or mHR6B (E214K), could
mediate degradation of the type 3 N-end rule substrates Ala-
gal, Ser-gal, or Thr-gal in ubr1 S. cerevisiae. (These pro-
teins are long-lived in either wild-type or ubr1 yeast [71].) The
results (Fig. 3B) indicated that mouse UBR1 lacked the activ-
ity of E3 Ub ligase.
Construction of UBR1/ mice. In the deletion-2 disruption
allele of mouse UBR1, exons 4 to 6 were replaced by a neo
cassette (Fig. 2A). Exons 4 to 6 encompassed a region of high
sequence conservation between the S. cerevisiae and mouse
UBR1 proteins (35). Moreover, these exons encompassed
amino acid positions that were previously found to be essential
for the integrity of the type 1 substrate-binding site (Gly147 and
Asp150) and the type 2 site (Asp233 and His236) in S. cerevisiae
UBR1. Specifically, mutations of these residues greatly im-
paired the activity of yeast UBR1 in mediating degradation of
either type 1 or type 2 N-end rule substrates (A. Webster, M.
FIG. 3. Mouse UBR1, in the presence of mouse E214K or HR6A, can rescue the N-end pathway in ubr1 S. cerevisiae. (A) Relative enzymatic
activities of gal in ubr1 S. cerevisiae expressing different combinations of the following components. (i) Type 1 (Arg-gal) or type 2 (Leu-gal)
N-end rule substrates; (ii) mouse UBR1 or the p414-MET25 vector alone (designated 414); and (iii) mouse E214K, mouse HR6A (homolog of
E214K), both of them together, or vector(s) alone (p415-MET25, designated 415, and p413-MET25, designated 413). The activities of X-gal test
proteins in wild-type (UBR1) S. cerevisiae are shown in the rightmost column. 100%, the activity of X-gal in ubr1 cells transformed with the
p414-MET25 vector alone. (B) Same as for panel A but with type 3 N-end rule substrates, Ala-gal (shaded bars), Ser-gal (hatched bars), or
Thr–-gal (black bars). (C) Pulse-chase analysis of Arg-gal (produced from Ub-Arg-gal) in ubr1 S. cerevisiae coexpressing either mouse UBR1
and the p415-MET25 vector (denoted 415), mouse HR6A E2 enzyme and the p414-MET25 vector (denoted 414), mouse UBR1 and HR6A, or
vectors alone. Time zero refers to the end of 5-min pulse. The asterisk indicates the 	90-kDa, long-lived gal cleavage product specific for
short-lived X-gal test proteins (3) in the pulse-chase with cells coexpressing mouse UBR1 and mouse HR6A. (Much smaller amounts of the
90-kDa species could also be detected in the pulse-chase with cells expressing mouse UBR1 alone.) (D) Quantitation of Arg-gal degradation
depicted in panel C (the decay curves shown are averages from two independent experiments). 100%, the initial amount of Arg-gal in cells
transformed with vectors alone (p414-MET25 and p415-MET25); , vectors alone; ‚, UBR1 and p415-MET25 (vector); E, HR6A and
p414-MET25 (vector); F, UBR1 and HR6A.
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Ghislain, and A. Varshavsky, unpublished data). Of the	1,000
ES cell clones resistant to both G418 and FIAU, 33 clones
contained the expected deletion or disruption (Fig. 2A), as
verified by PCR and Southern analyses (data not shown). Ten
of these correctly targeted ES cell clones were used to generate
male chimeras, and in five of them the UBR1 allele was
transmitted through the germ line. Male chimeras were mated
with either 129/SvEv or C57BL/6 females, yielding UBR1/
heterozygotes. Intercrosses of UBR1/ mice produced
UBR1/ progeny (Fig. 4B) at the expected Mendelian fre-
quency of 	25%. In addition, examination of embryos from
heterozygous matings did not suggest a significantly increased
embryonic lethality of UBR1/ mice (data not shown). This,
and the evidence below that UBR1/ mice lacked the UBR1
protein, indicated that UBR1 was not required for either
mouse embryonic development or postnatal viability.
The relevant genotype of UBR1/ mice was verified by
using both PCR and Southern analysis (Fig. 2B and C). North-
ern analysis with a UBR1 cDNA-derived probe containing ex-
clusively the region deleted in the UBR1 allele did not detect
UBR1-specific transcripts in the brain, testis, and liver of
UBR1/ mice (Fig. 2D, gel a). By contrast, a UBR1 probe that
encompassed both the deleted region and the 3-flanking (un-
deleted) region of UBR1 cDNA detected UBR1-specific tran-
scripts in both / and UBR1/ tissues (Fig. 2D, gel b). The
latter transcripts were smaller than / ones (Fig. 2D, gel b)
and were presumably the aberrantly spliced RNAs transcribed
from the PUBR1 promoter. To determine whether a version of
UBR1 protein was present in UBR1/ tissues, we carried out
immunoblot analyses with different antibodies to mouse UBR1
(see Materials and Methods). With SDS-PAGE-fractionated
extracts from the liver, skeletal muscle, and EF cells, these
antibodies detected the band of expected (	200 kDa) size in
/ tissues but not in their UBR1/ counterparts (Fig. 2E
and Fig. 5B and data not shown), indicating that UBR1/
mice (Fig. 4B) lacked the UBR1 protein.
Expression of mRNAs encoding components of the N-end
rule pathway and related proteins in UBR1/ and / mice.
Northern analysis was used to assess the levels of mouse mR-
NAs encoding NTAN1, ATE1, mHR6B, UBR1 (E3), and its
homologs UBR2 and UBR3 (Fig. 5A). After a 48-h fast, the
level of UBR1 mRNA in the / muscle increased by 	2-fold,
returning to approximately basal levels 24 h after refeeding
(Fig. 5A). The levels of UBR2 and UBR3 mRNAs also in-
creased upon fasting. Expression of UBR2 mRNA returned to
the basal (or slightly higher) level 24 h after refeeding, but the
level of UBR3 mRNA remained high (Fig. 5A). The level of
UBR2 mRNA was reproducibly higher in the UBR1/ muscle
under both normal and fasting conditions (Fig. 5A), suggesting
compensatory overexpression of UBR2 in UBR1/ mice. The
level of mRNA encoding mHR6B (E214K), one of UBR1-
interacting E2s (see above), changed in parallel with that of
UBR1. As to the N-end rule pathway’s components upstream
of Ub ligase, the levels of ATE1 mRNA also increased upon
fasting, in contrast to that of NTAN1 mRNA. A Northern
survey of other tissues showed that the levels of NTAN1, ATE1,
and mHR6B mRNAs in the UBR1/ brain, testis, and liver
did not change significantly, except that the testis-specific
NTAN1 transcript (1.1 kb) and ATE1 transcript (2 kb) were
decreased in UBR1/ mice (Fig. 5C).
We also asked whether an increased level of UBR1 mRNA
during fasting of / mice (Fig. 5A) was accompanied by an
increased level of the UBR1 protein. We observed no increase
(Fig. 5B), in agreement with data of Lecker et al. (38), who
assessed the levels of UBR1 mRNA and protein in the muscle
of normal versus diabetic rats. One possibility is that the UBR1
expression circuit is designed to maintain a constant level of
the UBR1 protein. Thus, the observed induction of UBR1
mRNA upon fasting or diabetes may be caused by enhanced
degradation of UBR1 under these conditions.
Extracts of UBR1/ skeletal muscle lack the N-end rule
pathway, in contrast to / extracts. Previous studies with
ATP-supplemented extracts from the skeletal muscle of rats
FIG. 4. Growth retardation and altered fat metabolism in UBR1/
mice. (A) Growth retardation in UBR1/ mice of the 129/C57 strain
background. Body masses of the offspring (total of 141 mice) from
UBR1/ heterozygous matings were determined from 1 day after
birth until adulthood. To keep track of newborn pups before they
could be distinguished using ear punching (at 3 weeks of age), the pups
were marked by applying spots of paint every day. At week 3 the
genotypes of pups were determined by using PCR with tail-derived
DNA. (A, graph a) Male masses as a function of age: 18 / (), 34
UBR1/ (Œ), and 20 UBR1/ mice (F) were used. (A, graph b) Same
as for panel A, graph a, but with females: 18 / (), 35 UBR1/
(Œ), and 16 UBR1/ mice (F) were used. (A, graph c) The mass ratios
of UBR1/ males to / males (f) and of UBR1/ females to /
females (E) as a function of age. The arrows in graphs a to c denote the
time of weaning (day 20). (B) A pair of 6-week-old / and UBR1/
male littermates. The mass of the UBR1/ mouse shown here was
15% lower than that of its / littermate. (C) Relative masses of
organs and tissues of UBR1/ mice, expressed as percentages of the
weights of age-matched / counterparts. Standard deviations are
indicated. For determining the masses of hind legs and hind leg fat
pads, 94 pairs of 2- to 4-month-old mice (69 male pairs and 25 female
pairs) were used (63 /, 31 UBR1/, and 94 UBR1/ mice, pro-
duced through matings of UBR1/ mice). For other measurements in
this panel, 24 pairs of 2- to 4-month-old mice (17/, 7 UBR1/, and
24 UBR1/ mice) were used. (D) Altered regulation of the FAS
mRNA in skeletal muscle of UBR1/ mice. Lanes a to f, Northern
analysis of FAS mRNA from skeletal muscle of / and UBR1/
mice that were either fed ad libitum, fasted for 48 h, or refed for 24 h
after the fast. Lanes g and h, FAS mRNA from growing EF cells (/
and UBR1/) in culture. Lanes i and j, the same as lanes c and d but
with a longer autoradiographic exposure. A 32P-labeled 1.1-kb FAS
cDNA fragment (nucleotides 535 to 1642; accession no. AAG02285)
was used as a probe.
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and rabbits demonstrated the presence of the N-end rule path-
way in the muscle and also showed that this pathway was
further induced during muscle atrophy caused by tumors, sep-
sis, or diabetes (38, 60, 62). To assess the activity of the N-end
rule pathway in skeletal muscles of / and UBR1/ mice,
we measured the ATP-dependent degradation of model N-end
rule substrates in muscle extracts (Fig. 6). The substrates used
were 35S-labeled, purified Ub-X-DHFR proteins (X  Met,
Arg, or Phe) (see Materials and Methods). Ub-X-DHFRs were
rapidly deubiquitylated in a muscle extract by ATP-indepen-
dent DUBs, yielding X-DHFR test proteins, similarly to the
results with extracts from other eukaryotic cells (12, 18). Arg-
DHFR and Phe-DHFR are, respectively, a type 1 and type 2
N-end rule substrates (see the introduction), whereas Met-
DHFR is not a substrate of the N-end rule pathway. Degra-
dation of X-DHFRs in ATP-supplemented / and UBR1/
extracts was measured by determining 5% TCA-soluble 35S.
Although the N-end rule-specific degradation of Arg-DHFR
and Phe-DHFR was only 	2-fold above the background of
nonspecific degradation (i.e., the degradation of Met-DHFR),
a much lower ratio than the one observed with rabbit reticu-
locyte extracts and similar substrates (18, 23, 29), the specific
degradation was reproducible in independent experiments
(data not shown). Moreover, the N-end rule specificity of deg-
radation could be independently verified by adding to an ex-
tract dipeptides bearing either type 1 or type 2 destabilizing
N-terminal residues. These dipeptides act as specific inhibitors
of either type 1 or type 2 substrate-binding sites of UBR1 (12,
18, 53).
The degradation of Phe-DHFR (a type 2 substrate) in ex-
tract from / muscle was reproducibly higher than in the
extract from UBR1/ muscle (Fig. 6A). Crucially, the extent
of degradation of Phe-DHFR in UBR1/ extract was essen-
tially indistinguishable from the level of background degrada-
tion observed with Met-DHFR (not an N-end rule substrate)
in either / or UBR1/ extracts (Fig. 6A and data not
shown). Moreover, the addition of Phe-Ala dipeptide to /
extract decreased the degradation of Phe-DHFR to back-
ground levels, whereas the same peptide had no effect on the
(already background-level) degradation of Phe-DHFR in
UBR1/ extract (Fig. 6A). Ala-Phe, a dipeptide of the same
composition but bearing a type 3 destabilizing N-terminal res-
idue, had no effect in either / or UBR1/ extracts (Fig.
6D). Finally, the addition of Lys-Ala dipeptide, bearing a type
1 destabilizing N-terminal residue, to / extract enhanced
the degradation of Phe-DHFR (Fig. 6A), whereas the same
dipeptide inhibited the degradation of Arg-DHFR (Fig. 6B).
These findings (Fig. 6A, B, and D) reproduced, in a muscle
extract, the previously observed phenomenon of type 1 dipep-
tides enhancing the degradation of type 2 N-end rule sub-
strates either in vivo (5) or in reticulocyte extract (18). Note
that the addition of type 1 dipeptide to UBR1/ extract had
no effect on the (background) levels of degradation of either
Arg-DHFR or Phe-DHFR in this extract, in contrast to the
effect of type 1 and type 2 dipeptides on the same substrates in
/ extract (Fig. 6A to D and data not shown).
We also measured, in / and UBR1/ extracts, the con-
jugation of Ub to 125I-labeled human -lactalbumin, a type 1
N-end rule substrate bearing N-terminal Lys (23, 38). For
these experiments, / and UBR1/ muscle extracts were
fractionated by DEAE-cellulose chromatography to yield frac-
tion II preparations, which contained most of the Ub system,
FIG. 5. Expression analysis of mouse UBR1 and functionally related genes in / and UBR1/ mice. (A) Northern analysis of skeletal muscle
mRNAs encoding UBR1, other components of the N-end rule pathway, and the UBR1 homologs UBR2 and UBR3. RNA was isolated from
skeletal muscle of control, 48-h fasted, or 24-h refed / and UBR1/ mice. See Materials and Methods and the legend to Fig. 4D for the fasting
and refeeding protocols. Northern blots were hybridized with 32P-labeled cDNA probes specific for the following genes: UBR1 (nucleotides 555
to 888, accession no. AF061555; this probe was specific for the deleted region in the UBR1 allele); UBR2 (a 0.3-kb probe encompassing the region
homologous to the one deleted in the UBR1/ allele; Y. T. Kwon and A. Varshavsky, unpublished data); UBR3 (a 0.4-kb probe; Y. T. Kwon and
A. Varshavsky, unpublished data); ATE1 (nucleotides 638 to 1734, accession no. AF079098); NTAN1 (nucleotides 34 to 900, accession no.
U57692); mHR6B (E214K) (nucleotides 115 to 569, accession no. U57690); and -actin. (B) The level of UBR1 protein in skeletal muscle is not
significantly altered upon fasting. Total extracts (	70 g per lane) from skeletal muscles of normally fed or 48-h fasted / and UBR1/ mice
were analyzed by immunoblotting, using affinity-purified antibody (38) against the N-terminal 	35-kDa fragment of mouse UBR1. (C) Northern
analysis of ATE1, NTAN1, and mHR6B (E214K) expression in the brain, liver, and testis of / and UBR1
/ mice by using DNA probes described
in the legend to panel A.
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including components of the N-end rule pathway, but lacked
free Ub (23, 61). AMP-PNP was used as the energy source in
these assays because it supported the activation of Ub by the
E1 enzyme but could not be utilized by the 26S proteasome
(61). The conjugation of added Ub to 125I-labeled -lactalbu-
min in fraction II from/muscle resulted, upon SDS-PAGE
and autoradiography, in a smear of multiubiquitylated -lact-
albumin derivatives (Fig. 5E, lane 2; compare with lane 1).
Previous work (65) has shown that E214K(C88S), an active-site
mutant of the E214K (HR6B) Ub-conjugating enzyme, traps
Ub in a stable ester-bond complex (through a reaction medi-
ated by E1 enzyme) and therefore acts as a dominant-negative
inhibitor of the E3-containing Ub ligase. Indeed, the addition
of either the purified E214K(C88S) protein or Lys-Ala dipep-
tide (a type 1 N-end rule inhibitor) to / fraction II abol-
ished the bulk of -lactalbumin ubiquitylation in this system
(Fig. 6E, lanes 4 and 6; compare with lane 2). By contrast, the
addition of Ala-Lys, bearing a type 3 destabilizing N-terminal
residue, had no effect on ubiquitylation of -lactalbumin (Fig.
6E, lane 8; compare with lane 2). Strikingly, the extent of
ubiquitylation of -lactalbumin in fraction II from UBR1/
muscle (Fig. 6E, lane 3; compare with lane 2) was essentially
indistinguishable from background ubiquitylation in the inhib-
ited / fraction II (Fig. 6E, lane 3; compare with lanes 4 and
6). Moreover, the background-level ubiquitylation in UBR1/
fraction II remained essentially unchanged upon the addition
of either E214K(C88S) or Lys-Ala, in contrast to the results
with / fraction II (Fig. 6E, lane 3; compare with lanes 5 and
7).
Previous work, which used dipeptide inhibitors and domi-
nant-negative E214K(C88S) in an attempt to distinguish be-
tween protein ubiquitylation due to the N-end rule pathway
and the total ubiquitylation of endogenous proteins in a frac-
tion II preparation from a / muscle extract suggested that
60 to 80% of the ATP-dependent degradation of soluble mus-
cle proteins was mediated by the N-end rule pathway (62). We
assayed the conjugation of 125I-Ub to endogenous proteins in
fraction II preparations from / and UBR1/ muscle. This
conjugation was found to be 25 to 30% lower in UBR1/
fraction II than in / fraction II (Fig. 6F, lanes 2 and 3;
compare with lane 1). Ubiquitylation of endogenous proteins
in both / and UBR1/ fraction II preparations was
strongly inhibited by the addition of dominant-negative
E214K(C88S) protein (Fig. 6F, lanes 4 and 5; compare with
lanes 2 and 3).
Thus, both degradation assays with purified N-end rule sub-
strates in / versus UBR1/ muscle extracts (Fig. 6A to D)
and ubiquitylation assays with 125I-labeled -lactalbumin in
/ versus UBR1/ fraction II (Fig. 6E) indicated that the
N-end rule pathway was virtually absent from skeletal muscle
FIG. 6. Extracts from skeletal muscle of UBR1/ mice lack the
N-end rule pathway. Degradation of 35S-labeled, purified Ub-X-
DHFR test proteins in extracts from skeletal muscle of / and
UBR1/ littermates (strain 129 background) was monitored by mea-
suring TCA-soluble 35S (see Materials and Methods). Open and closed
symbols denote, respectively, the data with/ and UBR1/ extracts.
(A) Degradation of Phe-DHFR, a type 2 N-end rule substrate.  and
f, no dipeptide inhibitor; E and F, Lys-Ala; ‚ and Œ, Phe-Ala; ƒ and
, Ala-Lys (control dipeptide). (B) Degradation of Arg-DHFR, a type
1 substrate.  and f, no dipeptide inhibitor; E and F, Lys-Ala; ‚ and
Œ, Phe-Ala; ƒ and , Ala-Lys. (C and D) The N-end rule-specific
degradation of Phe-DHFR is ATP-dependent. Reaction mixtures were
incubated at 37°C for 10 min without ATP followed by assays either in
the absence or the presence of added ATP. (Time zero corresponds to
the end of 10-min preincubation in the absence of ATP to allow
deubiquitylation of Ub-X-DHFRs.) (C) Degradation of Phe-DHFR in
the presence ( and f) or absence (E and F) of added ATP, and of
Met-DHFR (not an N-end substrate) in the presence (‚ and Œ) or
absence ( and ) of ATP. (D) Effect of Lys-Ala, a type 1 dipeptide
inhibitor, on the ATP-dependent degradation of Phe-DHFR, a type 2
N-end rule substrate.  and f, no inhibitor; E and F, Lys-Ala; ‚ and
Œ, Phe-Ala;  and , Ala-Lys; ƒ and , Ala-Phe. (E) Conjugation of
unlabeled Ub to 125I--lactalbumin (a type 1 N-end rule substrate) is
decreased in the extract from UBR1/ muscle. Some of the samples
contained either the dominant-negative E214K(C88S) mutant protein
(at 2 M), 2 mM Lys-Ala, or 2 mM Ala-Lys. Double arrowheads on
the left indicate the excess of unconjugated 125I--lactalbumin. Lane 1,
125I--lactalbumin alone. (F) Conjugation of 125I-Ub to endogenous
proteins is marginally decreased in a UBR1/ muscle extract com-
pared to that in the wild-type extract. Fraction II (see Materials and
Methods) of muscle extracts from / and UBR1/ mice was sup-
plemented with AMP-PNP, and the formation of 125I-Ub-protein con-
jugates was assayed by SDS-PAGE in the ab- sence (lanes 2 and 3) or
presence (lanes 4 and 5) of 2 M E214K(C88S). Arrowhead on the
right indicates the position of 125I-Ub-E214K(C88S) conjugate. Lane 1,
125I-Ub alone. The results shown in panels A through D are typical of
those obtained in at least five independent experiments, using three
independently produced muscle extract preparations, and two inde-
pendent EF cell extracts (see Fig. 7), in combination with two inde-
pendent preparations of [35S]Ub-X-DHFR.
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extracts of UBR1/ mice, in contrast to extracts from /
muscle. It remains to be determined whether the N-end rule
pathway is absent from the intact UBR1/ muscle.
The N-end rule pathway is active in UBR1/ fibroblasts.
We assayed the degradation of purified, 35S-labeled Phe-
DHFR, a type 2 N-end rule substrate, in ATP-supplemented
extracts from / and UBR1/ EF cell lines. Met-DHFR,
bearing a stabilizing N-terminal residue, was used as a negative
control. In striking contrast to the findings with UBR1/ mus-
cle extracts (Fig. 6), the N-end-rule-specific degradation of
Phe-DHFR not only was retained in UBR1/ EF extract but
was actually significantly higher in that extract than in the
otherwise identical extract from / EF cells (Fig. 7A, graph
a). A large fraction of Phe-DHFR degradation in both /
and UBR1/ EF extracts was mediated by the N-end rule
pathway (Fig. 7A, graph a; compare the decay curves of Phe-
DHFR with those of Met-DHFR, both in the presence and
absence of added ATP). As expected, Phe-Ala, a type 2 dipep-
tide inhibitor, reduced the degradation of Phe-DHFR in both
/ and UBR1/ EF extracts (Fig. 7A, graph c). Ala-Phe
(Fig. 7A, graph c) and Ala-Lys (not shown), both of them type
3 dipeptide inhibitors, did not have any effect on either / or
UBR1/ EF extracts, again as expected. Strikingly, however,
Lys-Ala, a type 1 dipeptide inhibitor, enhanced the degrada-
tion of Phe-DHFR only in / EF extract (see above for a
description of this previously discovered crossover enhancing
effect of type 1 dipeptides on degradation of type 2 N-end rule
substrates [18]). Specifically, whereas the degradation of Phe-
DHFR in / EF extract was enhanced by Lys-Ala (Fig. 7A,
graph b), which is similar to the results with / muscle
extracts described above (Fig. 6A and D), the same Lys-Ala
dipeptide not only did not enhance degradation of the same
substrate, Phe-DHFR, in UBR1/ EF extract but slightly (and
reproducibly) decreased it (Fig. 7A, graph b, and data not
shown).
Thus, the N-end rule pathway is active in UBR1/ EF
extracts (Fig. 7A, graph a) despite the absence of the UBR1
protein from UBR1/ EF cells (Fig. 2E, gel c). The selective
absence of enhancing effect of a type 1 dipeptide on degrada-
tion of type 2 N-end rule substrate in UBR1/ EF extract (Fig.
7A, graph b) suggests that non-UBR1 N-recognins that medi-
ate the N-end rule pathway in UBR1/ EF cells lack a struc-
tural feature that underlies the above allosteric effect in the
UBR1 N-recognin (E3).
To examine the in vivo degradation of N-end rule substrates
in / and UBR1/ EF cells, they were transiently trans-
fected with plasmids that expressed an X-nsP4gal test protein
(X  Met, Arg, or Tyr) as part of the DHFRh-UbR48-X-
nsP4gal fusion, a UPR construct (39, 66, 68, 69). In this Ub
fusion, the reference moiety DHFRh-UbR48 contained the ha
epitope-tagged mouse dihydrofolate reductase (DHFRh). DH-
FRh-UbR48-X-nsP4gal is cotranslationally cleaved by DUBs
at the UbR48-X junction, yielding the long-lived DHFRh-
UbR48 reference protein and a test protein, X-nsP4gal (X 
Met, Arg, or Tyr). In the UPR technique, the reference protein
serves as an internal control for the levels of expression, im-
munoprecipitation yields, sample volumes, and other sources
of sample-to-sample variation, thereby increasing the accuracy
of pulse-chase and related assays (39, 51, 66, 68, 69). The
nsP4gal moiety of X-nsP4gal comprised the first 165 resi-
dues of nsP4 (Sindbis virus polymerase) (13, 69), followed by
the E. coli gal moiety that lacked the first 5 residues of
wild-type gal. Due to a built-in reference protein in DHFRh-
UbR48-X-nsP4gals, it was possible to compare metabolic sta-
bilities of X-nsP4gals not only in pulse-chase assays but also
in pulse-only assays where we determined, after a 60-min
pulse, the ratio of an X-nsP4gal protein to the reference
protein DHFRh-UbR48 (Fig. 7B and C). Arg-nsP4gal was
metabolically unstable in both / and UBR1/ EF cells.
Specifically, 44 and 42% of Arg-nsP4gal (bearing a type 1
destabilizing N-terminal residue) remained after the 60-min
pulse in, respectively, the / and UBR1/ EF cells relative
to the long-lived Met-nsP4gal, whose amount at the end of a
60-min pulse was taken as 100% (Fig. 7B and C). Remarkably,
Phe-nsP4gal, bearing a type 2 destabilizing N-terminal resi-
due, was reproducibly more unstable in UBR1/ EF cells
(42%) than in/ EF cells (64%) (Fig. 7B and C). This in vivo
result was in agreement with the independent observation of
enhanced Phe-DHFR degradation in UBR1/ versus/ EF
extracts (Fig. 7A, graph a).
We carried out pulse-chase assays of N-end rule substrates
in / and UBR1/ EF cells by using UPR-type fusions of
fDHFRh-UbR48-X-nsP4f (X  Met, Arg, or Tyr). In these
fusions, the reporter moiety was X-nsP4f, the full-length 69-
kDa X-nsP4 protein (X  Met, Arg, or Tyr) bearing the C-
terminal flag epitope (2). UPR-based assays with X-nsP4 test
proteins in UBR1/ and / EF cells employed 10-min pulse
and chase times of 0, 1, and 2 h. The results (Fig. 7D and E)
confirmed that Arg-nsP4 (a type 1 substrate) and Tyr-nsP4 (a
type 2 substrate) were short-lived in both UBR1/ and /
EF cells. Moreover, the degradation of Arg-nsP4 and Tyr-nsP4
was slightly but reproducibly faster in UBR1/ cells (Fig. 7D
and E), in agreement with the findings using 1-h in vivo pulse
(Fig. 7B and C) as well as proteolysis in EF extracts (Fig. 7A).
Met-nsP4, bearing a stabilizing N-terminal residue, was long-
lived in both UBR1/ and / EF cells (Fig. 7D and E). In
UBR1/ EF cells, 23% of Arg-nsP4 remained at the end of
the 1-h chase, in contrast to 32% Arg-nsP4 in / EF cells
under the same conditions (Fig. 7D and E). Similarly, in
UBR1/ EF cells 25% of Tyr-nsP4 remained at the end of the
1-h chase, in contrast to 35% of Tyr-nsP4 in / EF cells
under the same conditions (Fig. 7D and E). We conclude that
the N-end rule activity was present and, moreover, hyperactive
in UBR1/ EF cells, which lacked the UBR1 protein (Fig. 7).
Reduced mass and other phenotypes of UBR1/ mice.
Most UBR1/ mice weighed significantly less than their /
and UBR1/ littermates of the same gender (Fig. 4A). The
	20% difference in mass observed at birth transiently in-
creased to 	32% for males and 	26% for females at the time
of weaning (Fig. 4A, graph c, arrow), when the pups’ nutrition
changes from mother’s milk to solid food. By 4 months the
mean difference in mass was 	20% (Fig. 7A, graph c) and
decreased to 	12% at 1 year (data not shown). Despite the
lower mass of UBR1/ mice, their mean body length (exclud-
ing their tails) was nearly indistinguishable from that of age-
matched, same-gender / mice (Fig. 4B and data not
shown). The lengths and weights of bones from UBR1/ mice
were also similar to those of their littermate / controls
(data not shown). The weights of brain, liver, spleen, kidney,
and testis of UBR1/ mice were 	90% or more of the cor-
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responding organ weights of either UBR1/ or / litter-
mates (Fig. 4C). However, the average weights of hind leg
muscle and the hind leg fat pad of UBR1/ mice were, re-
spectively, 	82 and 	61% of their UBR1/ and / coun-
terparts (Fig. 7C), suggesting that the lower total mass of
UBR1/ mice stemmed from a disproportionate decrease in
the mass of skeletal muscle and adipose tissues.
No gross morphological differences were observed between
UBR1/ and / embryos at any stage of development (data
not shown). The body masses of eight E17.5 / male em-
bryos, fifteen UBR1/ male embryos, and six UBR1/ male
embryos were, respectively, 714  41, 716  39, and 616  58
mg. Histological examinations of adult UBR1/ tissues (small
intestine, liver, pancreas, adrenal gland, thyroid gland, kidney,
ovary, heart, spleen, thymus, skeletal muscle, brain, and sciatic
nerve) did not detect significant abnormalities (data not
shown). UBR1/ mice appeared to be healthy; their limb
movements and overall behavior were apparently normal; they
oriented to sound and cared for offspring. Several behavioral
and motor coordination tests were also carried out. We used 24
adult UBR1/ mice (2 to 4 months old) whose weights were
	15% lower than those of their control littermates (8
UBR1/ and 16 / mice). Motor coordination of UBR1/
mice was assessed using rotarod (32). UBR1/ mice exhibited
a slightly lower ability to stay on a rotating horizontal rod than
their UBR1/ and / littermates (data not shown). The
cause of this phenotype is likely to be a reduced motor coor-
dination of UBR1/ mice rather than defects in learning and
memory (data not shown). No significant differences between
UBR1/ mice and their UBR1/ or / littermates were
observed in several previously described tests (32), including
the weight retention test (assessment of physical strength), the
coat hanger test (assessment of both physical strength and
coordination), and the hind paw footprint test (assessment of
walking patterns). Thus, despite the 15 to 20% lower mass of
UBR1/ mice, the above tests detected no overt behavioral or
locomotor impairments in these mice.
Mouse UBR1 (E3) functions in association with either
E214K (mHR6B) or mHR6A, two highly similar Ub-conjugat-
ing enzymes (Fig. 3). Previous work has shown that mice lack-
ing E214K (HR6B) are defective in spermatogenesis (55). We
examined whether UBR1/ mice exhibited defects in sper-
matogenesis. Comparison of various mating combinations
[(/ 
 /), (/ 
 /), (/ 
 /), and (/ 

/)] revealed no significant fertility defects in either male or
female UBR1/ mice, in that UBR1/ mice were apparently
normal in copulatory behavior, the size of testes, the number of
litters, and the average litter size (data not shown). Histolog-
ical examination of UBR1/ seminiferous tubules showed no
obvious abnormalities in either the structure of tubules, differ-
entiation of germ cells (mitotic, meiotic, and postmeiotic), or
morphology of supporting cells, such as Sertoli and Leydig cells
(data not shown). No differences in testicular cell apoptosis
was detected between UBR1/ and / testes by using the
TUNEL assay (data not shown). Thus, UBR1, in an otherwise
wild-type genetic background, is not required for fertility-re-
lated functions.
Abnormal fat metabolism in UBR1/ mice. To address the
cause of adipose tissue reduction in UBR1/ mice, we used
Northern analysis of RNA from / and UBR1/ skeletal
FIG. 7. The N-end rule pathway is retained in UBR1/ EF cells.
(A) Degradation of 35S-labeled Ub-X-DHFR proteins in extracts from
/ and UBR1/ EF cell lines was monitored by measuring TCA-
soluble 35S (see Materials and Methods). Open and closed symbols
denote the data with / and UBR1/ extracts, respectively. Reac-
tion mixtures were incubated at 37°C for 10 min without ATP, and
then ATP-dependent degradation of X-DHFR was initiated by the
addition of ATP (time zero). No ATP was added to control samples.
(A, graph a) ATP-dependent degradation of Phe-DHFR, a type 2
N-end rule substrate, is faster in extracts from UBR1/ EF cells.
Squares and circles, Phe-DHFR with or without ATP, respectively;
diamonds and triangles, Met-DHFR (not an N-end rule substrate)
with or without ATP, respectively. (A, graph b) Lys-Ala, a type 1
dipeptide inhibitor, does not enhance degradation of the type 2 N-end
rule substrate Phe-DHFR in UBR1/ EF extracts.  and f, no
inhibitor; E and F, Lys-Ala. (A, graph c) Effect of Phe-Ala, a type 2
dipeptide inhibitor, on the ATP-dependent degradation of Phe-
DHFR.  and f, no inhibitor; E and F, Phe-Ala; ƒ and , Ala-Phe.
(B) Immortalized / and UBR1/ EF cells were transiently trans-
fected with pRC/dhaUbXnsP4gal (X  Met, Arg, or Phe) expressing
X–-gal test proteins as parts of UPR-based DHFRh-UbR48-X-
nsP4gal fusions (39, 66, 68, 69). Cells were labeled for 1 h with
35S-methionine–cysteine followed by immunoprecipitation and SDS-
PAGE analysis of an X–-gal test protein and the DHFR-based ref-
erence protein. (C) Quantitation of the patterns shown in panel B
using PhosphorImager. Note a small but significant additional desta-
bilization of Phe-DHFR in UBR1/ EF cells. (D) Pulse-chase analysis
of the N-end rule pathway in / and UBR1/ EF cells. Immortal-
ized / and UBR1/ EF cells were transiently transfected with
pcDNA3flagDHFRhaUbXnsP4flag (X  Met, Arg, or Tyr) expressing
fDHFRh-UbR48-X-nsP4f, a UPR-based fusion yielding, cotranslation-
ally, the fDHFRh-UbR48 reference protein (denoted DHFR on the
right) and X-nsP4f (X-nsP4-flag) test protein, denoted X-nsP4 on the
right. Cells were labeled for 10 min with 35S-methionine–cysteine fol-
lowed by a chase for 0, 1, and 2 h in the presence of cycloheximide,
preparation of extracts, immunoprecipitation, SDS-PAGE, autoradiogra-
phy, and quantitation, essentially as described previously (39). (E) Quan-
titation of the patterns shown in panel D using a PhosphorImager. The
amounts of 35S in an X-nsP4f relative to 35S in the fDHFRh-UbR48 refer-
ence protein at the same time points were plotted as percentages of this
ratio for Met-nsP4f (bearing a stabilizing N-terminal residue) at time zero.
 and f, Met-nsP4; E and F, Arg-nsP4; ‚ and Œ, Tyr-nsP4.
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muscles, comparing the levels of mRNAs encoding some of the
proteins involved in fat metabolism, specifically gamma inter-
feron, interleukin 1 (IL-1), IL-6, tumor necrosis factor al-
pha, glycerol-3-phosphate transferase, triacyl glycerol lipase,
and fatty acid synthase (FAS). No significant differences be-
tween / and UBR1/ mice were observed in the levels of
the above mRNAs under normal, fasting, and refeeding con-
ditions (data not shown), except for the levels of FAS mRNA
(Fig. 4D). FAS is a multicatalytic enzyme containing domains
for acyl-carrier peptide and seven enzymatic modules required
for the conversion of acetyl-coenzyme A (CoA) and malonyl-
CoA to palmitate. The expression of FAS is tightly regulated
through nutritional, hormonal, and developmental inputs (41,
77)
Under normal conditions the level of FAS mRNA in the
UBR1/ muscle was 	56% of that in / muscle (Fig. 4D,
lanes a and b), suggesting that reduction of adipose tissue in
UBR1/ mice was caused at least in part by a decrease in FAS
expression. In contrast to skeletal muscle, the levels of FAS
mRNA in growing UBR1/ and/ EF cell lines were nearly
identical (Fig. 4D). After 48 h of fasting, the level of FAS
mRNA in / skeletal muscle was reduced to less than 3% of
its level under normal conditions (Fig. 4D, lanes c and i). In
striking contrast, the level of FAS mRNA in the muscle of
fasting UBR1/ mice remained nearly unchanged (Fig. 7D,
lanes d and j; compare with lanes c and i). Thus, whereas under
normal conditions the UBR1/ muscle contained half as
much FAS mRNA as the / muscle, after 48 h of fasting the
level of FAS mRNA became 	14-fold higher in the UBR1/
muscle than in the congenic / muscle (Fig. 4D). After 24 h
of refeeding, the levels of FAS mRNA in the UBR1/ and
/ muscles became nearly equal (Fig. 4D, lanes e and f).
Given the above results, several blood plasma parameters
were determined in multiple pairs of 2- to 4-month old /
and UBR1/ littermates (Table 1). Under normal conditions
the plasma glucose level of UBR1/ mice was 12% lower than
that of / mice. This difference in glucose levels between
UBR1/ and / mice increased to 21% after a 24-h fast and
remained nearly unchanged (20%) 24 h after refeeding (Table
1). These differences were reproducible in independent mea-
surements (data not shown). Thus, UBR1/ mice were mildly
hypoglycemic under normal conditions. The levels of plasma
triglycerides, urea nitrogen, total protein, and albumin were
also lower in UBR1/ mice, suggesting a state of mild mal-
nutrition (Table 1). There were no significant differences be-
tween UBR1/ mice and / littermates in the levels of
plasma cholesterol, as well as sodium, potassium, calcium,
chloride, and phosphorus (Table 1). UBR1/ mice were also
normal in their levels of several markers of the liver function,
including GGT, AST, and ALT (data not shown).
NTAN1/ UBR1/ double knockout mice. Our previous
work (32) described NTAN1/ mice which lacked the Asn-
specific NtN-amidase, a component of the N-end rule pathway
upstream of UBR1 (see the introduction). NTAN1/ mice
were viable, fertile, and of normal size, physical strength, and
motor coordination, but they exhibited altered behaviors, in-
cluding a socially conditioned exploratory phenotype (32).
NtN-amidase mediates the destabilizing activity of Asn, 1 of 16
destabilizing residues that are recognized directly or indirectly
by UBR1 (19, 35). In situ hybridization indicated similar spa-
tial patterns of UBR1 and NTAN1 expression in embryogenesis
(32, 35). Whereas NTAN1/ mice completely lacked NtN-
amidase activity (32), UBR1/ mice contained proteins that at
least partially complemented the activity of missing UBR1
(present work). It is unknown whether the function of NtN-
amidase is confined to the N-end rule pathway. To address the
possibility of unexpected interactions between NTAN1- and
UBR1-dependent functions, we produced double mutant
NTAN1/ UBR1/ mice through double heterozygous mat-
ings (see Materials and Methods). Adult NTAN1/ UBR1/
mice were fertile and apparently healthy. Intercrosses be-
tween NTAN1/ UBR1/ mice or between NTAN1/
UBR1/ mice yielded expected Mendelian frequencies of
NTAN1/ UBR1/ mice, indicating that the absence of both
NTAN1 and UBR1 did not significantly increase embryonic
lethality. NTAN1/ UBR1/ mice resembled UBR1/ mice
TABLE 1. Plasma parameters of UBR1/ and congenic / micea
Parameter (unit of measurement)
Results for the following mice groups:
Control Fasted Refed
Wild-type UBR1/ Wild-type UBR1/ Wild-type UBR1/
Glucose (mg/dl) 172  9.6 152  10.3c 162  10.4 128  8.5c 186  12.5 149  15.1c
Triglycerides (mg/dl) 56.8  6.7 44.5  5.1c 44.7  5.5 35.2  4.7d 61.0  6.9 46.2  5.8d
Cholesterol (mg/dl) 57.3  4.5 53.1  5.1 68.5  5.2 70.5  4.6 54.4  4.3 54.2  4.8
Albumin (g/dl) 1.40  0.17 1.27  0.12e 2.13  0.25 1.44  0.31c NDb ND
Urea nitrogen (mg/dl) 21.3  4.3 16.3  3.2d 27.3  5.1 20.5  4.7e ND ND
Total protein (g/dl) 3.23  0.41 3.02  0.34 4.33  0.57 3.34  0.52 ND ND
Sodium (mmol/liter) 147  1.3 148  1.6 153  1.5 153  1.5 148  1.7 149  1.9
Potassium (mmol/liter) 6.43  0.12 6.57  0.15 5.25  0.12 5.45  0.13 6.52  0.15 6.48  0.13
Chloride (mmol/liter) 116  1.6 116  1.5 122  1.4 124  0.6 116  1.7 117  1.5
Calcium (mg/dl) 7.47  0.21 7.43  0.23 8.15  0.27 7.35  0.21 7.18  0.36 7.42  0.26
Phosphorus (mg/dl) 11.5  0.46 12.4  0.34c 12.7  0.48 13.4  0.32d 11.7  0.51 12.1  0.69
a The experiments were performed twice (experiments 1 and 2), with 28 pairs of animals total. The blood was collected from 12 pairs before fasting (control), 8 pairs
after 24 h of fasting (fasted), and 8 pairs after 24 h of fasting and 24 h of refeeding (refed).
b ND, not determined.
c P  0.001.
d P  0.01.
e P  0.05.
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in being of lower weight (by 	20%) than their NTAN1/
UBR1/, NTAN1/ UBR1/, and NTAN1/ UBR1/ lit-
termates (data not shown), in contrast to the normal weight of
NTAN1/ mice (32). General behavior, physical strength, and
motor coordination of NTAN1/ UBR1/ mice were not
overtly abnormal, as assayed with the previously described (32)
rotarod test, weight retention test, and coat hanger test (data
not shown).
DISCUSSION
This study is the first in a projected series that aims to
decipher, in functional and mechanistic detail, the mammalian
N-end rule pathway at the level of the pathway’s E3 Ub ligases.
It was found that more than one E3 (N-recognin) mediates the
mouse N-end rule pathway, in contrast to S. cerevisiae. We
report the following results.
(i) The mouse UBR1-encoded 200-kDa N-recognin (E3)
(35) was shown to rescue the N-end rule pathway in ubr1 S.
cerevisiae that lacked the 225-kDa yeast homolog of mouse
UBR1. The rescue’s efficiency was strongly increased in the
presence of a cognate mouse E2 enzyme, either mHR6A or
mHR6B (E214K) (Fig. 3).
(ii) UBR1/ mouse strains lacking the UBR1 protein (Fig.
2) were viable, of normal fertility, and outwardly healthy, but
their mass, from birth through adulthood, was significantly
lower than that of their congenic / littermates (on average,
20% lower at 2 months of age) (Fig. 4). The lower mass of
UBR1/ mice stemmed at least in part from reduced mass of
skeletal muscle and adipose tissues. FAS mRNA, encoding
FAS, was underexpressed in UBR1/ muscle from normally
fed UBR1/ mice and was strikingly misregulated after a 48-h
fast (Fig. 7C). The growth retardation and decreased fat con-
tent in UBR1/ mice were consistent with a lower level of
glucose and triglycerides in the blood plasma of these mice
(Table 1).
(ii) Extracts of UBR1/ skeletal muscle lacked the N-end
rule pathway, in contrast to otherwise identical extracts from
/ muscle. This and other evidence (Fig. 6) suggested that
the N-end rule pathway was absent from cells of the UBR1/
skeletal muscle. By contrast, the N-end rule pathway was found
to be active and even slightly enhanced both in UBR1/ EF
cell lines in vivo and in EF extracts (Fig. 7).
(iv) Double-mutant NTAN1/ UBR1/ mice, which
lacked both NtN-amidase (see the introduction) and the UBR1-
encoded E3 Ub ligase, were viable and did not exhibit phe-
notypes other than the expected ones.
The main finding of this work is that the recognition of type
1 and type 2 N-end rule substrates by the mammalian N-end
rule pathway is mediated by more than one E3 Ub ligase
(N-recognin), in contrast to the yeast S. cerevisiae, where
UBR1 is the only E3 of the N-end rule pathway. Functionally
overlapping, differentially expressed N-recognins render
UBR1/ mice mosaic in regard to activity of the N-end rule
pathway. The previously identified mouse UBR2 and UBR3
genes (35) encode proteins that are, respectively, 47 and 25%
identical and 67 and 51% similar to mouse UBR1 (Y. T. Kwon,
T. Tasaki, and A. Varshavsky, unpublished data). S. cerevisiae
UBR1 is equally similar (22% identity, 42% similarity) to
mouse UBR1 and UBR2. Although UBR3 is clearly an E3 Ub
ligase of the same RING-H2 class as UBR1 and is a member
of the UBR sequence family, it lacks the N-terminus-proximal
residues that have previously been found to be essential for the
integrity of the type 1 and type 2 substrate-binding sites of S.
cerevisiae UBR1 (A. Webster, M. Ghislain, and A. Varshavsky,
unpublished data). UBR3 might be the still-unidentified E3
Ub ligase that recognizes N-terminal Ala, Ser, or Thr, the type
3 destabilizing residues of the mammalian N-end rule (18, 22).
In contrast to UBR3, mouse UBR2 is identical in size to
mouse UBR1 (200 kDa) and contains the residues identified as
essential for the recognition of type 1 or 2 substrates in S.
cerevisiae UBR1 (see above). In addition, the mouse UBR1 and
UBR2 genes have identical exon and intron junctions in the
first 12 exons that have been examined in detail (Y. T. Kwon
and A. Varshavsky, unpublished data). Recent in vitro binding
assays with model N-end rule substrates identified mouse
UBR2 as a type 1 and 2 N-recognin (Z. Xia, Y. T. Kwon, F.
Du, and A. Varshavsky, unpublished data), making it likely
that UBR2 is an E3 that at least partially rescues the N-end
rule pathway in UBR1/ mice. If so, it remains to be ex-
plained why extracts from the UBR1/ skeletal muscle, where
UBR2 is apparently expressed, lack the N-end rule pathway, in
contrast to identically prepared extracts from / muscle and
also in contrast to extracts from either UBR1/ or / EF
cells (see Results). Remarkably, recent results indicated that
UBR1 and UBR2 cannot be the only type 1 or 2 N-recognins
in the mouse. The UBR1/ UBR2/ double mutant mice are
embryonic lethals, in contrast to UBR1/ and UBR2/ mice;
nevertheless, EF cells rescued from arrested UBR1/
UBR2/ embryos do contain the N-end rule pathway, albeit
of significantly lower activity (Y. T. Kwon, I. Davydov, and A.
Varshavsky, unpublished data). The identity of a third mouse
type 1 and 2 N-recognin (E3) is unknown. This N-recognin
might be closer in sequence to that of the plant (Arabidopsis
thaliana) protein PRT1, which is not a member of the UBR
sequence family but shares with it the presence of a RING
finger and the ability to recognize destabilizing N-terminal
residues in model substrates (50). In contrast to UBR1, which
binds to both type 1 (basic) and type 2 (bulky hydrophobic)
destabilizing N-terminal residues, plant PRT1 binds to a subset
of type 2 N-terminal residues (A. Bachmair, personal commu-
nication), raising the possibility that a third mouse N-recognin
is PRT1-like in that it may be specific for subsets of N-terminal
residues that are recognized by N-recognins such as UBR1 and
UBR2.
The recently constructed UBR2/ mice are viable as males
but not as females, most of which die as embryos (Y. T. Kwon
and A. Varshavsky, unpublished data). UBR2/ EF cells con-
tain the N-end rule pathway, as would be expected given the
presence of UBR1 (E3) in UBR2/ mice. UBR2/ males
are of normal weight and appearance but are infertile owing to
death, through apoptosis, of meiotic spermatocytes in
UBR2/ testes (Y. T. Kwon and A. Varshavsky, unpublished
data). The death of meiotic spermatocytes in UBR2/ mice
may be caused by the lack of UBR1 (E3) expression in these
cells, a conjecture to be verified.
Several studies utilized dipeptides as inhibitors of the N-end
rule pathway in metazoan cells. The reported results include
the inhibition of mammalian cell differentiation (27, 47), the
inhibition of apoptosis in human lymphocytes (44), and the
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inhibition of limb regeneration in newts (67) by dipeptides
bearing destabilizing N-terminal residues. In contrast to S.
cerevisiae, where dipeptides added to the growth medium are
strong in vivo inhibitors of the N-end rule pathway (5), the
same dipeptides are, at most, weak inhibitors of the N-end rule
pathway in mammalian cells (F. Le´vy and A. Varshavsky, un-
published data). Moreover, if the design of S. cerevisiae UBR1
is relevant to mammalian N-recognins, it is clear that dipep-
tides can also activate rather than inhibit a substrate-binding
site of N-recognin that recognizes internal degrons in a subset
of its substrates (68). Given this issue alone, the discovery of
circuits controlled by the N-end rule pathway in multicellular
eukaryotes will require genetic analyses as well as identifica-
tion of the pathway’s physiological substrates.
Four functions of the N-end rule pathway have been iden-
tified so far: its essential roles in the control of peptide import
(68) and chromosome stability (51) in S. cerevisiae (see the
introduction), its essential role in mammalian spermatogenesis
(the phenotype of UBR2/ mice described above [Y. T. Kwon
and A. Varshavsky, unpublished data]), and its requirement for
cardiogenesis and angiogenic remodeling during mouse em-
bryogenesis (Y. T. Kwon, A. Kashina, and A. Varshavsky,
unpublished data). The latter function was discovered through
the construction of ATE1/ mouse strains that lacked R-
transferase (see the introduction). In contrast to the two roles
of the N-end rule pathway in yeast, where both the relevant
circuits and physiological substrates of UBR1 are partially un-
derstood (51, 68), we do not know, as yet, the identity of
proteins whose metabolic stabilization underlies the observed
phenotypes of UBR1/, UBR2/, and ATE1/ mouse
strains. The UBR1/ mice and cells of the present work will
be essential for further advances in the understanding of the
N-end rule pathway.
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